key: cord-0949118-pqt9kbwd
authors: Ashktorab, Hassan; Pizuorno, Antonio; Oskroch, Gholamreza; Fierro González, Nora Alma; Sherif, Zaki A.; Brim, Hassan
title: COVID-19 in Latin America: Symptoms, Morbidities and Gastrointestinal Manifestations
date: 2020-11-06
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.10.033
sha: 290ae09cd691be92ee4a449d676489b5d1619faf
doc_id: 949118
cord_uid: pqt9kbwd

nan

Latin America became the epicenter of the Coronavirus Disease 2019 (COVID-19) pandemic. Although the US still leads the world in the number of diagnosed cases (6, 204 ,000) and reported deaths (187,000), as of Sept. 5 th , 2020, Brazil (4,092,000 cases and 123,500 deaths) was second behind the US in both infections and deaths 1 . The leading affected countries contributing in both infection and deaths, respectively are Peru (683,700/29,680); Chile (420,400/11,500); Mexico (629,400/67,300); Colombia (658,450/21,100); Ecuador (118,045 /6,700); Argentina (451,100/9,400); and Bolivia (119,500/5,300). In this study, we described the clinical characteristics, mortality, and symptoms of the confirmed COVID-19 cases officially registered by countries that make pertinent information publicly available. Special emphasis was made on gastrointestinal symptoms (GI) and comorbidities in relation to disease outcome.

We analyzed data from SARS-CoV-2 positive patients evaluated at healthcare centers and hospitals of 8 Latin American countries (Brazil, Peru, Mexico, Argentina, Colombia, Venezuela, Ecuador, and Bolivia) between March 1 and July 30, 2020. These countries consist of a population that exceeds 519 million. Demographics, comorbidities and clinical symptoms were collected. The total cohort consisted of 728,282 patients. Common symptoms and comorbidities were combined and evaluated by weighted analysis methods. Correlation coefficients were calculated together with regression analysis to establish associations between comorbidities and lethality. The effect of symptoms was reported using weighted analysis. SPSS was used for this analysis.

A total of 728,282 patients tested positive for COVID-19 across all the 8 Latin American countries. Of these, 52.6% were female. The average age was 48.4 years. Peru had the oldest cohort with 56.8 years old and highest rate of females (56.8%) while Chile had the youngest cohort (39 years old). Venezuela had the highest male prevalence (56.7%). Most common symptoms were cough with 60.1% (Bolivia had the highest rate 78%), fatigue/tiredness with 52.0%, sore throat with 50.3%, and fever with 44.2%. Bolivia had fever as the top symptom (83.3%). GI symptoms including diarrhea (highest in Mexico with 22.9%, Fig 1) , nausea, vomiting, and abdominal pain were not associated with higher mortality. The collective death toll was 25,008 patients (3.4%). Hypertension was among the top (12.1%) comorbidities followed by diabetes with 8.3% and obesity 4.5%. In multivariable analyses, the leading and significant comorbidities were hypertension (r=0.83, p=0.02), diabetes (r=0.91, p=0.01), and obesity (r=0.86, p=0.03). Asthma (r=0.37, p=0.54) and increasing age (0.13 p=0.81) were not independently associated with higher mortality. Lethality was highest in Mexico (16.6%) and lowest in Venezuela (0.9%) among the analyzed cohorts (Fig. 1 ).

Our study revealed that COVID-19 manifests differently among the various regions of Latin America. These differences are important to consider since their impact can influence management, treatment and prevention strategies. The most common symptoms are dry cough, fatigue, sore throat and fever. The most common comorbidities are obesity, hypertension and diabetes. This contrasts with what was reported by Maechler et al, (common symptoms: fatigue, myalgia and cough while top comorbidities: chronic lung disease and chronic heart disease) 2 . Worth noting that these symptoms and comorbidities did not distribute similarly among the eight studied nations. Mexico and Chile followed a similar profile as far as comorbidities are concerned.

The prevalence of diarrhea was much higher than previously reported 3 . This is probably because a higher prevalence of diarrhea in Latin American populations exists prior to SARS-CoV-2 outbreak 4 . The cumulative lethality in Latin America is 3.4%, close to the one reported worldwide 1 . We understand that this lethality rate may be inflated compared to the actual risk of death because the people most likely to get tested for COVID-19 are those with severe symptoms, not asymptomatic or mild symptoms patients. Analyzing the impact of the top comorbidities on lethality showed that obesity, hypertension and diabetes were highly correlated with lethality.

Another pertinent element to highlight, is that the prevalence of tuberculosis in our study was above 1.2%. There is a well-known high prevalence of tuberculosis in the region and the usage of BCG vaccination in Latin America. Many studies reported a potential effect of the BCG vaccine in providing heterologous protection 5 against other infections like the one from SARS-CoV-2. While the BCG vaccine role is still debated, future large and well-designed comparative studies might reveal whether it played any role in the pandemic's outcome in Latin America.

Some of the observed differences between countries have to do with pandemic management and data availability. Indeed, Venezuela for example showed the least lethality, which might be explained by free access to healthcare system and the fact that the treatment protocol includes hospitalizing every reported positive case 6 . This is in contrast to other countries such as Mexico where only severe disease patients are hospitalized and less access to advanced care is available for the general population 7 .

While the mechanisms of GI manifestations elicited by SARS-CoV-2 are still unknown, it is clear that ACE2 expression in the esophagus, small and large intestines, plays a role. Indeed, ACE2 was reported to be coexpressed with TMPRSS2 that is needed for the cleavage of the spike protein and the facilitation of the virus entry into the host GI system aggravating systemic effects of the virus and elevating the rates of transmission. While millions of patients have been discharged and tested negative in their nasopharyngeal specimens, a sizable portion still tested positive in their stools 8 . This group of patients should be the focus of next stringent monitoring methods as they are likely to play a role in the dissemination and recurrence of the disease. It will also be worth monitoring whether SARS CoV-2 persistence in the GI system will impact overall GI system functions.

In, conclusion, nearly, 10.5%-53% of patients with COVID-19 have GI manifestations. Differential clinical symptoms were associated with COVID-19 in Latin America countries. Metabolic syndrome components were the main comorbidities associated with poor outcome. Country-specific management and prevention plans are needed. 

Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

The epidemiology of rotavirus diarrhea in Latin America. Anticipating rotavirus vaccines

Could BCG be used to protect against COVID-19?

Power Popular Ministry of Health. Actualizacion of hospitalization and discharge criteria for suspected, proba-ble and confirmed cases of COVID-19

COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission